Gamida Cell Ltd.'s NiCord?? Receives FDA And European Medicines Agency Orphan Drug Designation

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development for the investigational medicinal product NiCordA for the treatment of acute lymphoblastic leukemia , acute myeloid leukemia , Hodgkin lymphoma and myelodysplastic syndrome . The FDA orphan drug designation coincides with the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products regarding NiCordA as a treatment for AML.

http://ift.tt/1DusxAi